COMPANY

Afasci, Inc.

Profile checked Oct 10, 2026

Keywords: Neuropathic Pain Inflammatory Pain Lumbosacral Radiculopathy Alcohol Alcohol Use Disorders Alcohol Abuse Alcohol Abuse/addiction Anxiety Pain Threshold Depression Disorders Sleep Disorder AFA-281

4Trials (company is sponsor)

Timeline

Apr 1, 2027 Trial start Phase 2: Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain source ↗
Oct 1, 2025 Trial start Phase 2: A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder source ↗
Jul 31, 2025 Grant Government grant — SBIR: $50,000 (annual award, as published), announced Jul 31, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Jul 1, 2025 Trial start I: A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers source ↗
Apr 11, 2023 Trial start I: Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers source ↗

Upcoming milestones

Jun 1, 2027 (ESTIMATED) · Phase 2 · A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder · NCT06710431
Mar 31, 2032 (ESTIMATED) · Phase 2 · Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain · NCT06649747

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jul 31, 2025 Government grant — SBIR: $50,000 (annual award, as published), announced Jul 31, 2025. Agency: NIH/NINDS. Source: government award database. source ↗

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT05547503	Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers	I	Completed	Apr 11, 2023	Dec 4, 2024 (actual)
NCT06649747	Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain	Phase 2	Not yet recruiting	Apr 1, 2027	Mar 31, 2032 (estimated)
NCT06719908	A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers	I	Not yet recruiting	Jul 1, 2025	Jul 1, 2026 (estimated)
NCT06710431	A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder	Phase 2	Not yet recruiting	Oct 1, 2025	Jun 1, 2027 (estimated)